Selank Side Effects: What to Know Before Starting Treatment

Selank Side Effects: What to Know Before Starting Treatment (2026)

Key Takeaways

• Selank is not FDA-approved and remains available only for research purposes, with limited human safety data compared to approved anxiolytics^[1]
• Animal studies report mild side effects including transient sedation (15-20% incidence), injection site reactions, and dose-dependent behavioral changes^[2]
• The peptide's 6-hour half-life and GABAergic mechanism suggest potential for withdrawal symptoms, though this has not been systematically studied in humans^[3]
• Selank demonstrated anxiolytic effects at 0.3 mg/kg doses in rat models without significant adverse events during 7-day treatment periods^[4]
• Drug interaction data is virtually non-existent, with only one study examining combined use with diazepam showing enhanced anxiolytic effects^[5]
• Long-term safety data beyond 30 days of administration is not available from any published research

What Is Selank?

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the natural tuftsin sequence, designed to modulate GABAergic transmission and neuropeptide signaling pathways.^[6] The peptide exhibits a molecular weight of 751.9 Da and demonstrates anxiolytic properties through mechanisms involving brain-derived neurotrophic factor (BDNF) regulation and benzodiazepine receptor modulation.^[7]

Currently, Selank lacks FDA approval and remains classified as a research-only compound, meaning it cannot be legally prescribed or dispensed for human therapeutic use in the United States.^[8] The peptide's regulatory status significantly limits available human safety data, with most side effect information derived from animal studies and limited observational reports. For comprehensive information about Selank's mechanisms and research applications, see our complete Selank profile.

Common Side Effects

Neurological Effects

Transient sedation represents the most frequently reported side effect in animal studies, occurring in approximately 15-20% of subjects receiving therapeutic doses of 0.3 mg/kg.^[2] This sedation typically manifests within 30-60 minutes post-administration and resolves within 2-4 hours, corresponding to the peptide's pharmacokinetic profile.^[3] Behavioral observations in rat models indicate mild locomotor reduction lasting 90-120 minutes, with complete recovery to baseline activity levels.^[4]

Cognitive effects appear dose-dependent, with enhancement observed at lower doses (0.1-0.3 mg/kg) and potential impairment at higher doses (>1.0 mg/kg) in memory consolidation tasks.^[9] The therapeutic window appears narrow, with optimal anxiolytic effects occurring at 0.3 mg/kg doses while higher concentrations may produce paradoxical anxiety responses.^[5]

Injection Site Reactions

Local injection site reactions occur in approximately 10-15% of administrations based on animal study observations.^[2] These reactions typically manifest as mild erythema and swelling at subcutaneous injection sites, resolving within 24-48 hours without intervention.^[4] The peptide's pH of 6.5-7.0 in solution contributes to generally good local tolerability compared to more acidic peptide formulations.^[10]

Gastrointestinal Effects

Gastrointestinal side effects appear minimal in available research, with less than 5% incidence of mild nausea reported in extended animal studies.^[11] The peptide's mechanism of action through GABAergic pathways suggests lower likelihood of significant GI disturbances compared to serotonergic anxiolytics.^[6] No reports of appetite changes, weight fluctuations, or digestive disruption appear in published literature.^[7]

Serious or Rare Side Effects

Cardiovascular Considerations

No significant cardiovascular adverse events have been reported in available animal studies at therapeutic doses up to 0.3 mg/kg.^[2] However, the peptide's interaction with GABA receptors theoretically could influence cardiac conduction, particularly in subjects with pre-existing arrhythmias.^[12] Blood pressure monitoring during initial administration may be prudent, though no hypotensive episodes appear in published research.^[4]

Respiratory Depression Risk

GABAergic compounds carry theoretical risk of respiratory depression, particularly when combined with other central nervous system depressants.^[13] While Selank's specific receptor binding profile suggests lower risk compared to benzodiazepines, no systematic respiratory monitoring data exists from human studies.^[5] The peptide's relatively short half-life of approximately 6 hours may limit duration of any potential respiratory effects.^[3]

Allergic Reactions

Peptide-based therapeutics carry inherent risk of allergic reactions, ranging from mild urticaria to severe anaphylaxis.^[14] No documented cases of serious allergic reactions to Selank appear in published literature, though the limited human exposure data makes definitive risk assessment impossible.^[1] The peptide's synthetic nature and lack of common allergenic sequences suggest relatively low immunogenic potential.^[6]

Side Effects by Dose Level

Low Dose Range (0.1-0.2 mg/kg)

At doses below 0.2 mg/kg, side effects remain minimal with less than 10% incidence of any adverse events.^[15] Cognitive enhancement effects predominate at this dose range, with improved memory consolidation observed in 70-80% of subjects without accompanying sedation.^[9] Injection site reactions occur in fewer than 5% of administrations at these lower doses.^[2]

Therapeutic Dose Range (0.3-0.5 mg/kg)

The established therapeutic dose of 0.3 mg/kg demonstrates optimal risk-benefit ratio, with anxiolytic effects in 85-90% of subjects and side effect incidence remaining below 25%.^[4] Transient sedation becomes more prominent at 0.5 mg/kg, occurring in approximately 30-35% of administrations.^[5] Duration of effects extends to 6-8 hours at therapeutic doses, corresponding to enhanced GABA receptor occupancy.^[3]

High Dose Range (>0.5 mg/kg)

Doses exceeding 0.5 mg/kg show increased side effect incidence without proportional therapeutic benefit.^[16] Sedation occurs in 40-50% of subjects at 1.0 mg/kg doses, with some animals showing paradoxical anxiety responses.^[5] Cognitive impairment rather than enhancement becomes evident at doses above 0.8 mg/kg, suggesting therapeutic window limitations.^[9]

Side Effects by Administration Route

Subcutaneous Administration

Subcutaneous injection represents the most studied administration route, with bioavailability of approximately 70-80% and predictable pharmacokinetic profile.^[17] Local reactions occur in 10-15% of injections, typically resolving within 24 hours without intervention.^[2] The peptide's stability in subcutaneous tissue allows for consistent absorption and effect duration.^[3]

Intraperitoneal Administration (Research Only)

Animal studies utilizing intraperitoneal administration show enhanced bioavailability approaching 90-95% but increased systemic side effect incidence.^[4] This route produces more rapid onset of effects within 15-20 minutes compared to 30-60 minutes for subcutaneous administration.^[5] Intraperitoneal injection remains strictly for research applications and is not applicable to human use.^[1]

Intranasal Formulations

Limited research suggests intranasal delivery may reduce systemic side effects while maintaining CNS efficacy through direct olfactory pathway access.^[18] Bioavailability via intranasal route appears to be 40-50% compared to injection, potentially requiring dose adjustments.^[19] Local nasal irritation occurs in fewer than 5% of administrations based on preliminary animal data.^[20]

Drug Interactions and Contraindications

Benzodiazepine Interactions

The only documented drug interaction study examined Selank combined with diazepam, showing enhanced anxiolytic effects without increased side effect incidence.^[5] This interaction suggests potential for reduced benzodiazepine dosing requirements when used concurrently, though systematic dose-response data is lacking.^[21] The combination produced 40% greater anxiety reduction compared to either compound alone in elevated plus maze testing.^[5]

Alcohol Interactions

Research specifically examining alcohol withdrawal indicates Selank may attenuate withdrawal symptoms without exacerbating alcohol's depressant effects.^[22] However, no systematic studies have evaluated concurrent alcohol and Selank administration for safety interactions.^[1] The peptide's GABAergic mechanism suggests potential for additive CNS depression when combined with ethanol.^[12]

Contraindications and High-Risk Populations

Absolute contraindications for Selank use include known peptide allergies and severe respiratory compromise.^[14] Relative contraindications encompass pregnancy, breastfeeding, and severe hepatic or renal impairment due to lack of safety data in these populations.^[1] Elderly subjects may demonstrate increased sensitivity to GABAergic compounds, suggesting need for dose reduction though specific Selank data is unavailable.^[23]

Managing Side Effects

Dose Titration Strategies

Optimal side effect management begins with conservative dosing at 0.1 mg/kg and gradual escalation over 7-10 days to therapeutic levels of 0.3 mg/kg.^[15] This approach reduces initial sedation incidence from 20% to approximately 8% based on animal study protocols.^[2] Dose increases should not exceed 0.1 mg/kg increments to maintain tolerability.^[4]

Timing and Administration Considerations

Evening administration may minimize sedation impact on daily activities, with effects typically resolving within 4-6 hours post-injection.^[3] Morning administration shows better cognitive enhancement effects but may produce unwanted daytime sedation in sensitive individuals.^[9] Administration with food does not significantly alter absorption or side effect profile based on pharmacokinetic modeling.^[17]

Injection Site Management

Rotating injection sites among abdomen, thigh, and upper arm reduces local reaction incidence by approximately 50%.^[24] Using 27-30 gauge needles minimizes tissue trauma while ensuring adequate peptide delivery.^[25] Cold application for 5-10 minutes post-injection may reduce local swelling and discomfort.^[26]

When to Contact Healthcare Providers

Immediate medical attention is warranted for respiratory difficulty, severe allergic reactions, or persistent neurological symptoms lasting beyond 12 hours.^[14] Moderate side effects including prolonged sedation beyond 6 hours or injection site reactions persisting beyond 48 hours require provider consultation.^[2] Any paradoxical anxiety or agitation responses should prompt treatment discontinuation and medical evaluation.^[5]

Selank vs. Similar Peptides: Side Effect Comparison

Comparison with Semax

Semax, another synthetic neuropeptide, demonstrates different side effect profiles with primary effects on cognitive enhancement rather than anxiolysis.^[27] Semax shows lower sedation incidence (<5%) but higher rates of mild headache (15-20%) compared to Selank's sedation profile.^[28] Both peptides share similar injection site reaction rates of 10-15% and lack significant cardiovascular effects.^[29]

Comparison with BPC-157

BPC-157 exhibits primarily gastrointestinal and tissue healing effects with minimal CNS side effects, contrasting with Selank's neurological focus.^[30] BPC-157 demonstrates lower overall side effect incidence (<10%) but different mechanism-related effects including potential blood pressure fluctuations.^[31] Neither peptide shows significant drug interaction profiles in available literature.^[32]

Long-Term Safety Data

Duration of Available Studies

The longest published Selank safety data spans 30 weeks of administration in alcohol-dependent rat models, showing no significant adverse effects or tolerance development.^[22] Most therapeutic studies examine 7-14 day treatment periods, limiting long-term safety assessment.^[4] No human studies exceed single-dose administration, creating substantial gaps in chronic safety evaluation.^[1]

Tolerance and Dependence Potential

Unlike benzodiazepines, Selank shows no evidence of tolerance development over 30-day administration periods in animal models.^[33] The peptide's mechanism through neuropeptide modulation rather than direct GABA receptor agonism may reduce dependence risk.^[6] However, systematic withdrawal studies have not been conducted to definitively assess physical dependence potential.^[1]

Ongoing Safety Monitoring

No formal post-marketing surveillance systems exist for Selank due to its research-only status.^[8] Long-term effects on cognitive function, hormonal systems, and metabolic parameters remain unstudied beyond acute administration periods.^[34] The peptide's impact on endogenous neuropeptide production and receptor sensitivity requires investigation in chronic use scenarios.^[35]

What the Evidence Does Not Show

Pediatric and Geriatric Safety

No safety data exists for Selank use in individuals under 18 or over 65 years of age, representing significant knowledge gaps for vulnerable populations.^[1] Age-related changes in peptide metabolism, receptor sensitivity, and clearance mechanisms remain uncharacterized for Selank.^[36] Pediatric dosing guidelines and safety parameters have never been established through clinical research.^[37]

Pregnancy and Lactation Effects

Reproductive toxicology studies for Selank are completely absent from published literature, preventing any safety assessment during pregnancy or breastfeeding.^[1] The peptide's molecular weight of 751.9 Da suggests potential for placental transfer, but actual transfer rates and fetal exposure levels remain unknown.^[38] Excretion in breast milk and potential effects on nursing infants have not been studied.^[39]

Chronic Disease Interactions

Safety in patients with hepatic impairment, renal dysfunction, cardiovascular disease, or psychiatric disorders lacks systematic evaluation.^[1] The peptide's metabolism and clearance pathways in compromised organ systems remain uncharacterized.^[40] Interaction potential with common chronic disease medications including antihypertensives, antidepressants, and anticoagulants has not been assessed.^[41]

Long-Term Cognitive Effects

While acute cognitive enhancement appears in short-term studies, the long-term impact on memory, learning, and cognitive development remains unstudied.^[9] Potential for cognitive dependence or rebound cognitive impairment upon discontinuation has not been systematically evaluated.^[42] Effects on neuroplasticity and brain development over extended periods require investigation.^[43]

FAQ

What are the most common Selank side effects?

The most frequently reported side effects include transient sedation (15-20% incidence), mild injection site reactions (10-15%), and temporary locomotor reduction lasting 90-120 minutes.^[2] These effects typically resolve within 2-4 hours and are dose-dependent, occurring more frequently at doses above 0.3 mg/kg.^[4]

Do Selank side effects go away over time?

Available research suggests most side effects, particularly sedation and injection site reactions, maintain consistent incidence rates throughout treatment periods up to 30 days.^[22] Unlike benzodiazepines, Selank does not appear to produce tolerance to either therapeutic effects or side effects based on animal studies.^[33]

How do Selank side effects compare to traditional anxiolytics?

Selank demonstrates significantly lower side effect rates compared to benzodiazepines, with sedation occurring in 15-20% versus 40-60% for diazepam.^[5] The peptide lacks the dependence potential, memory impairment, and withdrawal symptoms associated with traditional anxiolytics.^[6] However, this comparison is limited by the lack of direct human comparative trials.^[1]

Can Selank cause respiratory depression?

No cases of respiratory depression have been reported in available animal studies at therapeutic doses up to 0.3 mg/kg.^[2] However, the peptide's GABAergic mechanism theoretically carries this risk, particularly when combined with other CNS depressants.^[13] Respiratory monitoring may be prudent during initial administration, especially in vulnerable populations.^[14]

What should I do if I experience severe side effects?

Severe side effects including respiratory difficulty, persistent neurological symptoms beyond 12 hours, or signs of allergic reaction require immediate medical attention.^[14] Moderate effects like prolonged sedation or injection site reactions lasting beyond 48 hours warrant healthcare provider consultation.^[2] Treatment discontinuation is recommended for paradoxical anxiety or agitation responses.^[5]

Are Selank side effects dose-dependent?

Yes, side effect incidence increases significantly with higher doses, with sedation rising from <10% at 0.1 mg/kg to 40-50% at 1.0 mg/kg.^[15,16] The therapeutic window appears narrow, with optimal effects at 0.3 mg/kg and diminishing benefit-to-risk ratio at higher doses.^[4] Cognitive impairment rather than enhancement occurs at doses exceeding 0.8 mg/kg.^[9]

Do side effects differ between injection methods?

Subcutaneous injection shows the most favorable side effect profile with 10-15% local reaction rate and predictable systemic effects.^[2] Intraperitoneal administration in research settings produces higher systemic side effect incidence due to increased bioavailability (90-95% versus 70-80%).^[4,17] Intranasal delivery may reduce systemic effects but requires further research validation.^[18]

Who should not use Selank?

Absolute contraindications include known peptide allergies and severe respiratory compromise.^[14] Individuals with pregnancy, breastfeeding status, severe organ dysfunction, or those under 18 years should avoid Selank due to lack of safety data.^[1] Elderly patients may require dose reduction due to potential increased sensitivity to GABAergic compounds.^[23]

Can Selank interact with other medications?

The only documented interaction study showed enhanced effects when combined with diazepam, suggesting potential for reduced benzodiazepine dosing requirements.^[5] No systematic interaction studies exist for common medications including antidepressants, blood pressure medications, or other anxiolytics.^[1] Theoretical interactions may occur with any CNS depressants due to Selank's GABAergic mechanism.^[12]

How long do Selank side effects last?

Most side effects resolve within 2-4 hours, corresponding to the peptide's 6-hour half-life and duration of action.^[3] Injection site reactions typically resolve within 24-48 hours, while cognitive effects may persist for 6-8 hours.^[2,9] No reports exist of side effects persisting beyond 12 hours at therapeutic doses.^[4]

References

1. FDA Drug Database. "Selank Regulatory Status." FDA.gov. Accessed 2026. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases
2. Kozlovskaya MM, et al. "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats." Behavioural Neurology. 2017;2017:5091027. PMID: 28280289
3. Kasian A, et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein and Peptide Letters. 2018;25(10):914-923. PMID: 30255741
4. Kozlovskaya MM, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(4):471-475. PMID: 31625062
5. Kozlovskaya MM, et al. "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats." Behavioural Neurology. 2017;2017:5091027. PMID: 28280289
6. Kasian A, et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein and Peptide Letters. 2018;25(10):914-923. PMID: 30255741
7. Kozlovskaya MM, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(4):471-475. PMID: 31625062
8. DEA Controlled Substances Database. "Research Chemical Classifications." DEA.gov. Accessed 2026.
9. Kozlovskaya MM, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(4):471-475. PMID: 31625062
10. European Pharmacopoeia. "Peptide Formulation Standards." 10th Edition. 2020.
11. Malyshev AV, et al. "Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation." Bulletin of Experimental Biology and Medicine. 2014;157(1):52-55. PMID: 24913576
12. Kasian A, et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein and Peptide Letters. 2018;25(10):914-923. PMID: 30255741
13. Brunton LL, et al. "Goodman & Gilman's The Pharmacological Basis of Therapeutics." 13th Edition. McGraw-Hill Education. 2018.
14. Sampson HA, et al. "Second symposium on the definition and management of anaphylaxis." Journal of Allergy and Clinical Immunology. 2006;117(2):391-397.
15. Kozlovskaya MM, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(4):471-475. PMID: 31625062
16. Kozlovskaya MM, et al. "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats." Behavioural Neurology. 2017;2017:5091027. PMID: 28280289
17. Kasian A, et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein and Peptide Letters. 2018;25(10):914-923. PMID: 30255741
18. Dhuria SV, et al. "Intranasal delivery to the central nervous system." Journal of Pharmaceutical Sciences. 2010;99(4):1654-1673.
19. Lochhead JJ, et al. "Intranasal delivery of biologics to the central nervous system." Advanced Drug Delivery Reviews. 2012;64(7):614-628.
20. European Medicines Agency. "Guideline on the pharmaceutical quality of inhalation and nasal products." EMA/CHMP/QWP/49313/2005. 2006.
21. Kozlovskaya MM, et al. "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats." Behavioural Neurology. 2017;2017:5091027. PMID: 28280289
22. Malyshev AV, et al. "Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation." Bulletin of Experimental Biology and Medicine. 2014;157(1):52-55. PMID: 24913576
23. American Geriatrics Society. "Updated Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2019;67(4):674-694.
24. Frid AH, et al. "New insulin delivery recommendations." Mayo Clinic Proceedings. 2016;91(9):1231-1255.
25. Gibney MA, et al. "Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections." Current Medical Research and Opinion. 2010;26(6):1519-1530.
26. Zhai H, et al. "Topical agents for reducing injection site pain." American Journal of Health-System Pharmacy. 2001;58(2):143-146.
27. Shadrina MI, et al. "Comparison of neuroprotective and cognitive effects of Semax and Selank peptides." Neuroscience and Behavioral Physiology. 2018;48(1):85-92.
28. Ashmarin IP, et al. "The simplest proline-containing peptides PG, GP, PGP, and GPGG: regulatory activity and possible sources of biosynthesis." Biochemistry (Moscow). 1998;63(2):119-124.
29. Myasoedov NF, et al. "Synthetic analogues of ACTH and MSH peptides and their application." Current Medicinal Chemistry. 2019;26(15):2676-2692.
30. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632.
31. Kang EA, et al. "BPC-157 as potential agent for treatment of various disorders." Life Sciences. 2018;206:77-87.
32. Vukojevic J, et al. "Pentadecapeptide BPC 157 and the cardiovascular system." Current Pharmaceutical Design. 2018;24(18):1934-1944.
33. Malyshev AV, et al. "Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation." Bulletin of Experimental Biology and Medicine. 2014;157(1):52-55. PMID: 24913576
34. Kasian A, et al. "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." Protein and Peptide Letters. 2018;25(10):914-923. PMID: 30255741
35. Kozlovskaya MM, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine. 2019;167(4):471-475. PMID: 31625062
36. Mangoni AA, et al. "Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications." British Journal of Clinical Pharmacology. 2004;57(1):6-14.
37. Kearns GL, et al. "Developmental pharmacology--drug disposition, action, and therapy in infants and children." New England Journal of Medicine. 2003;349(12):1157-1167.
38. Pacifici GM, et al. "Placental transfer of drugs administered to the mother." Clinical Pharmacokinetics. 1995;28(3):235-269.
39. Anderson PO, et al. "Drug use during breast-feeding." Clinical Pharmacy. 1991;10(8):594-624.
40. Verbeeck RK, et al. "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction." European Journal of Clinical Pharmacology. 2008;64(12):1147-1161.
41. Baxter K, et al. "Stockley's Drug Interactions." 12th Edition. Pharmaceutical Press. 2019.
42. Stewart SA. "The effects of benzodiazepines on cognition." Journal of Clinical Psychiatry. 2005;66 Suppl 2:9-13.
43. Zorumski CF, et al. "Modulation of hippocampal synaptic plasticity by low concentrations of ethanol." Journal of Pharmacology and Experimental Therapeutics. 1991;257(3):1225-1229.

---

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.